Cholesterol-embolization syndrome: current perspectives

References

• Kronzon I, Saric M. Cholesterol embolization syndrome. Circulation. 2010;122:631–641. doi:10.1161/CIRCULATIONAHA.109.88646520697039
   PubMed Web of Science ®Google Scholar
• Modi KS, Rao VK. Atheroembolic renal disease. J Am Soc Nephrol. 2001;12:1781–1787.11461954
   PubMed Web of Science ®Google Scholar
• Quinones A, Saric M. The cholesterol emboli syndrome in atherosclerosis. Curr Atheroscler Rep. 2013;15(4):315. doi:10.1007/s11883-013-0315-y23423524
   PubMed Web of Science ®Google Scholar
• Scolari F, Bracchi M, Valzorio B, et al. Cholesterol atheromatous embolism: an increasingly recognized cause of acute renal failure. Nephrol Dial Transplant. 1996;11:1607–1612.8856220
   PubMed Web of Science ®Google Scholar
• Tunick PA, Nayar AC, Goodkin GM, et al. Effect of treatment on the incidence of stroke and other emboli in 519 patients with severe thoracic aortic plaque. Am J Cardiol. 2002;90:1320. doi:10.1016/S0002-9149(02)02870-912480041
   PubMed Web of Science ®Google Scholar
• Carroccio A, Olin JW, Ellozy SH, et al. The role of aortic stent grafting in the treatment of atheromatous embolization syndrome: results after a mean of 15 months follow-up. J Vasc Surg. 2004;40:424. doi:10.1016/j.jvs.2004.06.03615337868
   PubMed Web of Science ®Google Scholar
• Cross S. How common is cholesterol embolism? J Clin Pathol. 1991;44:859–861. doi:10.1136/jcp.44.12.10181960221
   PubMed Web of Science ®Google Scholar
• Drost H, Buis B, Haan D, Hillers JA. Cholesterol embolism as a complication of left heart catheterisation. Report of seven cases. Br Heart J. 1984;52:339–342. doi:10.1136/hrt.52.3.3396466520
   PubMedGoogle Scholar
• Moolenaar W, Lamers CB. Cholesterol crystal embolization in the Netherlands. Arch Intern Med. 1996;156:653–657. doi:10.1001/archinte.1996.004400600810098629877
   PubMedGoogle Scholar
• Ramirez G, O’Neill WM, Lambert R, Bloomer HA. Cholesterol embolization: a complication of angiography. Arch Intern Med. 1978;138:1430–1432. doi:10.1001/archinte.1978.03630340096035686939
   PubMedGoogle Scholar
• Fukumoto Y, Tsutsui H, Tsuchihashi M, et al. The incidence and risk factors of cholesterol embolization syndrome, a complication of cardiac catheterization: a prospective study. J Am Coll Cardiol. 2003;42:211. doi:10.1016/S0735-1097(03)00579-512875753
   PubMed Web of Science ®Google Scholar
• Blankenship JC, Butler M, Garbes A. Prospective assessment of cholesterol embolization in patients with acute myocardial infarction treated with thrombolytic vs conservative therapy. Chest. 1995;107:662. doi:10.1378/chest.107.3.6627874934
   PubMed Web of Science ®Google Scholar
• Jones DB, Iannacone PM. Atheromatous emboli in renal biopsies. An ultrastructural study. Am J Pathol. 1975;78:261–276.1115220
   PubMed Web of Science ®Google Scholar
• Lie JT. Cholesterol atheromatous embolism. The great masquerader revisited. Pathol Annu. 1992;27:17–50.1584626
   PubMedGoogle Scholar
• Preston RA, Stemmer CL, Materson BJ, Perez-Stable E, Pardo V. Renal biopsy in patients 65 years of age or older. An analysis of the results of 334 biopsies. J Am Geriatr Soc. 1990;38:669–674.2358629
   PubMed Web of Science ®Google Scholar
• Haas M, Spargo BH, Wit EJ, Meehan SM. Etiologies and outcome of acute renal insufficiency in older adults: a renal biopsy study of 259 cases. Am J Kidney Dis. 2000;35:433–447. doi:10.1016/S0272-6386(00)70196-X10692269
   PubMed Web of Science ®Google Scholar
• Dizman N, Aydın Bahat K, Özkanlı Ş, Özkök A. Cholesterol embolization syndrome: a report of two cases. Turk Kardiyol Dern Ars. 2016;44(3):251–255. doi:10.5543/tkda.2015.9458727138317
   PubMedGoogle Scholar
• Dahlberg PJ, Frecentese DF, Cogbill TH. Cholesterol embolism: experience with 22 histologically proven cases. Surgery. 1989;105(6):737–746.2727901
   PubMed Web of Science ®Google Scholar
• Hitti WA, Wali RK, Weinman EJ, Drachenberg C, Briglia A. Cholesterol embolization syndrome induced by thrombolytic therapy. Am J Cardiovasc Drugs. 2008;8(1):27–34. doi:10.2165/00129784-200808010-0000418303935
   PubMed Web of Science ®Google Scholar
• Li X, Bayliss G, Zhuang S. Cholesterol crystal embolism and chronic kidney disease. Int J Mol Sci. 2017;18(6):1120.
   PubMed Web of Science ®Google Scholar
• Duewell P, Kono H, Rayner KJ, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature. 2010;464:1357–1361. doi:10.1038/nature0894020428172
   PubMed Web of Science ®Google Scholar
• Kiyotake R, Oh-Hora M, Ishikawa E, Miyamoto T, Ishibashi T, Yamasaki S. Human mincle binds to cholesterol crystals and triggers innate immune responses. J Biol Chem. 2015;290:25322–25332. doi:10.1074/jbc.M115.64523426296894
   PubMed Web of Science ®Google Scholar
• Fukumoto Y, Shimokawa H, Kozai T, et al. Vasculoprotective role of inducible nitric oxide synthase at inflammatory coronary lesions induced by chronic treatment with interleukin-1 beta in pigs in vivo. Circulation. 1997;96:3104–3111. doi:10.1161/01.CIR.96.9.31049386181
   PubMed Web of Science ®Google Scholar
• Ridker PM. Intrinsic fibrinolytic capacity and systemic inflammation: novel risk factors for arterial thrombotic disease. Haemostasis. 1997;27:2–11.9439752
   PubMedGoogle Scholar
• Hammerschmidt DE, Greenberg CS, Yamada O, Craddock PR, Jacob HS. Cholesterol and atheroma lipids activate complement and stimulate granulocytes. A possible mechanism for amplification of ischemic injury in atherosclerotic states. J Lab Clin Med. 1981;98:68–77.6265570
   PubMed Web of Science ®Google Scholar
• Snyder HE, Shapiro JL. A correlative study of atheroembolism in human beings and experimental animals. Surgery. 1961;49:195–204.
   Web of Science ®Google Scholar
• Cosio FG, Zager RA, Sharma HM. Atheroembolic renal disease causes hypocomplementaemia. Lancet. 1985;2:118–121. doi:10.1016/S0140-6736(85)90225-92862317
   PubMed Web of Science ®Google Scholar
• Scolari F, Tardanico R, Zani R, et al. Cholesterol crystal embolism: a recognizable cause of renal disease. Am J Kidney Dis. 2000;36(6):1089–1109.11096032
   PubMed Web of Science ®Google Scholar
• Haqqie SS, Urizar RE, Singh J. Nephrotic-range proteinuria in renal atheroembolic disease: report of four cases. Am J Kidney Dis. 1996;28(4):493. doi:10.1016/S0272-6386(96)90458-88840937
   PubMed Web of Science ®Google Scholar
• Carvajal JA, Anderson WR, Weiss L, Grismer J, Berman R. Atheroembolism: an etiologic factor in renal insufficiency, gastrointestinal hemorrhages, and peripheral vascular diseases. Arch Intern Med. 1967;119:593–599. doi:10.1001/archinte.1967.002902401150095298059
   PubMedGoogle Scholar
• Goldman M, Thoua Y, Dhaene M, Toussaint C. Necrotising glomerulonephritis associated with cholesterol microemboli. Br Med J. 1985;290:205–206. doi:10.1136/bmj.290.6463.2053917753
   PubMedGoogle Scholar
• Frock J, Bierman M, Hammeke M, Reyes A. Atheroembolic renal disease: experience with 22 patients. Nebr Med J. 1994;79:317–321.
   PubMedGoogle Scholar
• Meyrier A, Buchet P, Simon P, Fernet M, Rainfray M, Callard P. Atheromatous renal disease. Am J Med. 1988;85(2):139. doi:10.1016/S0002-9343(88)80332-23400690
   PubMed Web of Science ®Google Scholar
• Eliot RS, Kanjuh VI, Edwards JE. Atheromatous embolism. Circulation. 1964;30:611–618.14211824
   PubMed Web of Science ®Google Scholar
• Scolari F, Ravani P, Pola A, et al. Predictors of renal and patient outcomes in atheroembolic renal disease: a prospective study. J Am Soc Nephrol. 2003;14:1584–1590.12761259
   PubMed Web of Science ®Google Scholar
• Saric MKronzon I. Embolism from atherosclerotic plaque: atheroembolism (cholesterol crystal embolism). 2019. Avaialble from: https://www.uptodate.com/contents/embolism-from-atherosclerotic-plaque-atheroembolism-cholesterol-crystal-embolism. Accessed May 25, 2019.
   Google Scholar
• O’Keeffe ST, Woods BO, Breslin DJ, Tsapatsaris NP. Blue toe syndrome: causes and management. Arch Intern Med. 1992;152:2197–2202. doi:10.1001/archinte.1992.004002300230041444678
   PubMed Web of Science ®Google Scholar
• Thadhani RI, Camargo CA Jr, Xavier RJ, Fang LS, Bazari H. Atheroembolic renal failure after invasive procedures. Natural history based on 52 histologically proven cases. Medicine (Baltimore). 1995;74(6):350. doi:10.1097/00005792-199511000-000057500898
   PubMed Web of Science ®Google Scholar
• Scolari FGCPalevsky PM. Clinical presentation, evaluation, and treatment of renal atheroemboli. 2018. Available from: https://www.uptodate.com/contents/clinical-presentation-evaluation-and-treatment-of-renal-atheroemboli. Accessed May 25, 2019.
   Google Scholar
• Tunick PA, Rosenzweig BP, Katz ES, Freedberg RS, Perez JL, Kronzon I. High risk for vascular events in patients with protruding aortic atheromas: a prospective study. J Am Coll Cardiol. 1994;23(5):1085.8144773
   PubMed Web of Science ®Google Scholar
• Tunick PA, Kronzon I. Protruding atherosclerotic plaque in the aortic arch of patients with systemic embolization: a new finding seen by transesophageal echocardiography. Am Heart J. 1990;120(3):658. doi:10.1016/0002-8703(90)90024-R2389701
   PubMed Web of Science ®Google Scholar
• Scolari F, Ravani P, Gaggi R, et al. The challenge of diagnosing atheroembolic renal disease: clinical features and prognostic factors. Circulation. 2007;116(3):298. doi:10.1161/CIRCULATIONAHA.106.68099117606842
   PubMed Web of Science ®Google Scholar
• Saklayen MG, Gupta S, Suryaprasad A, Azmeh W. Incidence of atheroembolic renal failure after coronary angiography. A prospective study. Angiology. 1997;48(7):609. doi:10.1177/0003319797048007079242158
   PubMed Web of Science ®Google Scholar
• Ascione R, Ghosh A, Reeves BC, et al. Retinal and cerebral microembolization during coronary artery bypass surgery: a randomized, controlled trial. Circulation. 2005;112:3833–3838. doi:10.1161/CIRCULATIONAHA.105.55746216365207
   PubMed Web of Science ®Google Scholar
• Rudnick MR, Berns JS, Cohen RM, Goldfarb S. Nephrotoxic risks of renal angiography: contrast media-associated nephrotoxicity and atheroembolism–a critical review. Am J Kidney Dis. 1994;24(4):713. doi:10.1016/S0272-6386(12)80235-67942832
   PubMed Web of Science ®Google Scholar
• Scolari F, Ravani P. Atheroembolic renal disease. Lancet. 2010;375(9726):1650. doi:10.1016/S0140-6736(09)62073-020381857
   PubMed Web of Science ®Google Scholar
• Blackshear JL, Zabalgoitia M, Pennock G, et al. Warfarin safety and efficacy in patients with thoracic aortic plaque and atrial fibrillation. SPAF TEE Investigators. Stroke prevention and atrial fibrillation. Transesophageal echocardiography. Am J Cardiol. 1999;83(3):453. doi:10.1016/S0002-9149(98)00886-810072242
   PubMedGoogle Scholar
• Rosansky SJ, Deschamps EG. Multiple cholesterol emboli syndrome after angiography. Am J Med Sci. 1984;288:45–48. doi:10.1097/00000441-198407000-000126465195
   PubMed Web of Science ®Google Scholar
• Oda H, Miida T, Sato H, Higuma N. Treatment of unstable angina with cholesterol embolization as a complication of left heart catheterization. Jpn Circ J. 1990;54:487–492. doi:10.1253/jcj.54.4872232112
   PubMedGoogle Scholar
• Johnson LW, Esente P, Giambortolomei A, et al. Peripheral vascular complications of coronary angioplasty by the femoral and brachial techniques. Cathet Cardiovasc Diagn. 1994;31:165–172. doi:10.1002/ccd.18103103028025931
   PubMedGoogle Scholar
• Kooiman J, Seth M, Dixon S, et al. Risk of acute kidney injury after percutaneous Coronary interventions using radial versus femoral access. insights from the blue cross blue shield of Michigan cardiovascular consortium. Circ Cardiovasc Interv. 2014;7:190–198. doi:10.1161/CIRCINTERVENTIONS.113.00077824569598
   PubMed Web of Science ®Google Scholar
• Ando G, Cortese B, Russo F, et al. Acute kidney injury after radial or femoral access for invasive acute Coronary syndrome management, AKI-MATRIX. J Am Coll Cardiol. 2017;69:2592–2603. doi:10.1016/j.jacc.2016.11.026
   Web of Science ®Google Scholar
• Vuurmans T1, Byrne J, Fretz E, et al. Chronic kidney injury in patients after cardiac catheterisation or percutaneous coronary intervention: a comparison of radial and femoral approaches (from the British Columbia Cardiac and Renal Registries). Heart. 2010;96(19):1538–1542. doi:10.1136/hrt.2009.19229420668106
   PubMed Web of Science ®Google Scholar
• Falanga V, Fine MJ, Kapoor WN. The cutaneous manifestations of cholesterol crystal embolization. Arch Dermatol. 1986;122(10):1194. doi:10.1001/archderm.1986.016602201120243767406
   PubMedGoogle Scholar
• Fine MJ, Kapoor W, Falanga V. Cholesterol crystal embolization: a review of 221 cases in the English literature. Angiology. 1987;38(10):769. doi:10.1177/0003319787038010073310742
   PubMed Web of Science ®Google Scholar
• Donohue KG, Saap L, Falanga V. Cholesterol crystal embolization: an atherosclerotic disease with frequent and varied cutaneous manifestations. J Eur Acad Dermatol Venereol. 2003;17(5):504. doi:10.1046/j.1468-3083.2003.00710.x12941082
   PubMed Web of Science ®Google Scholar
• Zucchelli P, Zuccalà A. The diagnostic dilemma of hypertensive nephrosclerosis: the nephrologist’s view. Am J Kidney Dis. 1993;21:87–91. doi:10.1016/0272-6386(93)70100-D
   PubMed Web of Science ®Google Scholar
• Mayo RR, Swartz RD. Redefining the incidence of clinically detectable atheroembolism. Am J Med. 1996;100:524–529. doi:10.1016/S0002-9343(95)00059-38644764
   PubMed Web of Science ®Google Scholar
• Belenfant X, Meyrier A, Jacquot C. Supportive treatment improves survival in multivisceral cholesterol crystal embolism. Am J Kidney Dis. 1999;33:840–850.10213638
   PubMed Web of Science ®Google Scholar
• Theriault J, Agharazzi M, Dumont M, Pichette V, Ouimet D, Leblanc M. Atheroembolic renal failure requiring dialysis: potential for renal recovery? A review of 43 cases. Nephron Clin Pract. 2003;94:c11–c18. doi:10.1159/00007081912806187
   PubMedGoogle Scholar
• Greenberg A, Bastacky SI, Iqbal A, Borochovitz D, Johnson JP. Focal segmental glomerulosclerosis associated with nephrotic syndrome in cholesterol atheroembolism: clinicopathological correlations. Am J Kidney Dis. 1997;29:334–344. doi:10.1016/S0272-6386(97)90193-19041208
   PubMed Web of Science ®Google Scholar
• Meyrier A. Cholesterol crystal embolism: diagnosis and treatment. Kidney Int. 2006;69(8):1308–1312. doi:10.1038/sj.ki.500026316614719
   PubMed Web of Science ®Google Scholar
• Lai CK, Randhawa PS. Cholesterol embolization in renal allografts: a clinicopathologic study of 12 cases. Am J Surg Pathol. 2007;31:536–545. doi:10.1097/PAS.0b013e31802b30e317414100
   PubMed Web of Science ®Google Scholar
• Ripple M, Charney D, Nadasdy T. Cholesterol embolization in renal allografts. Transplantation. 2000;69:2221–2225. doi:10.1097/00007890-200005270-0005010852632
   PubMed Web of Science ®Google Scholar
• Darsee JR. Cholesterol embolism: the great masquerader. South Med J. 1979;72:174–180. doi:10.1097/00007611-197902000-00017371003
   PubMed Web of Science ®Google Scholar
• Mulay SR, Evan A, Anders HJ. Molecular mechanisms of crystal-related kidney inflammation and injury. Implications for cholesterol embolism, crystalline nephropathies and kidney stone disease. Nephrol Dial Transplant. 2014;29:507–514. doi:10.1093/ndt/gft24824163269
   PubMed Web of Science ®Google Scholar
• Gonzalez AP, Juega J, Vazquez C, et al. Late onset of cholesterol embolism leading to graft failure after renal transplantation: report of two cases. Transplant Proc. 2015;47:2361–2363. doi:10.1016/j.transproceed.2015.09.00526518927
   PubMed Web of Science ®Google Scholar
• Saleem S, Lakkis FG, Martinez-Maldonado M. Atheroembolic renal disease. Semin Nephrol. 1996;16:309–318.8829269
   PubMed Web of Science ®Google Scholar
• Dalakos TG, Streeten DH, Jones D, Obeid A. ‘Malignant’ hypertension resulting from atheromatous embolization predominantly of one kidney. Am J Med. 1974;7:135–138. doi:10.1016/0002-9343(74)90778-5
   Google Scholar
• Lye WC, Cheah JS, Sinniah R. Renal cholesterol embolic disease. Case report and review of the literature. Am J Nephrol. 1993;13:489–493. doi:10.1159/0001686698141186
   PubMed Web of Science ®Google Scholar
• Moolenaar W, Lamers CB. Gastrointestinal blood loss due to cholesterol crystal embolization. J Clin Gastroenterol. 1995;21(3):220. doi:10.1097/00004836-199510000-000118648057
   PubMed Web of Science ®Google Scholar
• Ben-Horin S, Bardan E, Barshack I, Zaks N, Livneh A. Cholesterol crystal embolization to the digestive system: characterization of a common, yet overlooked presentation of atheroembolism. Am J Gastroenterol. 2003;98(7):1471–1479. doi:10.1111/j.1572-0241.2003.07532.x12873565
   PubMed Web of Science ®Google Scholar
• Moolenaar W, Lamers CB. Cholesterol crystal embolization to liver, gallbladder, and pancreas. Dig Dis Sci. 1996;41(9):1819. doi:10.1007/BF020887528794801
   PubMed Web of Science ®Google Scholar
• Ezzeddine MA, Primavera JM, Rosand J, Hedley-Whyte ET, Rordorf G. Clinical characteristics of pathologically proved cholesterol emboli to the brain. Neurology. 2000;54:1681–1683. doi:10.1212/WNL.54.8.168110762515
   PubMed Web of Science ®Google Scholar
• Hollenhorst RW. Significance of bright plaques in the retinal arterioles. JAMA. 1961;178:23. doi:10.1001/jama.1961.0304040002500513908419
   PubMed Web of Science ®Google Scholar
• Bunt TJ. The clinical significance of the asymptomatic Hollenhorst plaque. J Vasc Surg. 1986;4(6):559. doi:10.1016/0741-5214(86)90169-23783831
   PubMed Web of Science ®Google Scholar
• Babikian V, Wijman CA, Koleini B, Malik SN, Goyal N, Matjucha IC. Retinal ischemia and embolism. Etiologies and outcomes based on a prospective study. Cerebrovasc Dis. 2001;12(2):108. doi:10.1159/00004768911490104
   PubMed Web of Science ®Google Scholar
• Trono R, Sutton C, Hollman J, Suit P, Ratliff NB. Multiple myocardial infarctions associated with atheromatous emboli after PTCA of saphenous vein grafts. A clinicopathologic correlation. Cleve Clin J Med. 1989;56:581–584. doi:10.3949/ccjm.56.6.5812805320
   PubMed Web of Science ®Google Scholar
• Moolenaar W, Lamers CBHW. Cholesterol crystal embolization and the digestive system. Scand J Gastroenterol. 1991;188:69–72. doi:10.3109/00365529109111232
   Google Scholar
• Mondragon P, Descombes E, Bollmann J, et al. Penile necrosis in a haemodialysis patient: a rare manifestation of cholesterol crystal embolism. Nephrol Dial Transplant. 1998;13:3233–3235.9870501
   PubMed Web of Science ®Google Scholar
• Robinson R, Pemberton M, Goddard M. Myositis due to cholesterol emboli. Postgrad Med J. 1993;69:947–949. doi:10.1136/pgmj.69.818.9478121874
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Oelberg DA, Mark EJ, Kanarek DH. Pulmonary cholesterol crystal embolization. Chest. 1997;112:1687–1692.9404775
   PubMed Web of Science ®Google Scholar
• Wilson DM, Salazer TL, Farkouh ME. Eosinophiluria in atheroembolic renal disease. Am J Med. 1991;91(2):186. doi:10.1016/0002-9343(91)90013-N1867244
   PubMed Web of Science ®Google Scholar
• Kumar A, Turney JH. Vasculitis look-alikes: variants of renal atheroembolic disease. Nephrol Dial Transplant. 1999;14:2053. doi:10.1093/ndt/14.8.2053
   PubMedGoogle Scholar
• Smith SC Jr, Allen J, Blair SN, et al., AHA/ACC, National Heart, Lung, and Blood Institute. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation. 2006;113(19):2363. doi:10.1161/CIRCULATIONAHA.106.17451616702489
   PubMed Web of Science ®Google Scholar
• Tousoulis D, Psarros C, Demosthenous M, Patel R, Antoniades C, Stefanadis C. Innate and adaptive inflammation as a therapeutic target in vascular disease: the emerging role of statins. J Am Coll Cardiol. 2004;63:2491–2502. doi:10.1016/j.jacc.2014.01.054
   Google Scholar
• Akdim F, Van Leuven SI, Kastelein JJ, G. Stroes E. Pleiotropic effects of statins: stabilization of the vulnerable atherosclerotic plaque? Curr Pharm Des. 2007;13:1003–1012. doi:10.2174/13816120778048754817430164
   PubMed Web of Science ®Google Scholar
• Yonemura K, Ikegaya N, Fujigaki Y, Suzuki H, Togawa A, Hishida A. Potential therapeutic effect of simvastatin on progressive renal failure and nephrotic-range proteinuria caused by renal cholesterol embolism. Am J Med Sci. 2001;322:50–52. doi:10.1097/00000441-200107000-0001011465248
   PubMed Web of Science ®Google Scholar
• Woolfson RG, Lachmann H. Improvement in renal cholesterol emboli syndrome after simvastatin. Lancet. 1998;351:1331–1332. doi:10.1016/S0140-6736(05)79058-99643803
   PubMed Web of Science ®Google Scholar
• Ishiyama K, Sato T, Taguma Y. Low-density lipoprotein apheresis ameliorates renal prognosis of cholesterol crystal embolism. Ther Apheresis Dial. 2015;19:355–360. doi:10.1111/1744-9987.12345
   PubMed Web of Science ®Google Scholar
• Tsunoda S, Daimon S, Miyazaki R, et al. LDL apheresis as intensive lipid-lowering therapy for cholesterol embolism. Nephrol Dial Transplant. 1999;14:1041–1042. doi:10.1093/ndt/14.4.1041b
   PubMed Web of Science ®Google Scholar
• Tamura K, Umemura M, Yano H, et al. Acute renal failure due to cholesterol crystal embolism treated with LDL apheresis followed by corticosteroid and candesartan. Clin Exp Nephrol. 2003;7:67–71. doi:10.1007/s10157-003-0243-114586747
   PubMedGoogle Scholar
• Mann SJ, Sos TA. Treatment of atheroembolization with corticosteroids. Am J Hypertens. 2001;14(8 Pt 1):831.11497203
   PubMed Web of Science ®Google Scholar
• Desai M, Ram R, Prayaga A, Dakshinamurty KV. Cholesterol crystal embolization (CCE): improvement of renal function with high-dose corticosteroid treatment. Saudi J Kidney Dis Transpl. 2011;22:327–330.21422636
   PubMedGoogle Scholar
• Stabellini N, Cerretani D, Russo G, Rizzioli E, Gilli P. Renal atheroembolic disease: evaluation of the efficacy of corticosteroid therapy. G Ital Nefrol. 2002;19:18–21.12165941
   PubMedGoogle Scholar
• Yucel A, Kart-Koseoglu H, Demirhan B, Ozdemir F. Cholesterol crystal embolization mimicking vasculitis: success with corticosteroid and cyclophosphamide therapy in two cases. Rheumatol Int. 2006;26:454–460. doi:10.1007/s00296-005-0012-416025335
   PubMed Web of Science ®Google Scholar
• Nakayama M, Izumaru K, Nagata M, et al. The effect of low-dose corticosteroids on short- and long-term renal outcome in patients with cholesterol crystal embolism. Ren Fail. 2011;33:298–306. doi:10.3109/0886022X.2011.61896821401354
   PubMed Web of Science ®Google Scholar
• Sullivan TP, King LE, Boyd AS. Colchicine in dermatology. J Am Acad Dermatol. 1998;39:993–999. doi:10.1016/S0190-9622(98)70275-09843014
   PubMed Web of Science ®Google Scholar
• Martínez GJ, Celermajer DS, Patel S. The NLRP3 inflammasome and the emerging role of colchicine to inhibit atherosclerosis-associated inflammation. Atherosclerosis. 2018;269:262–271. doi:10.1016/j.atherosclerosis.2017.12.02729352570
   PubMed Web of Science ®Google Scholar
• Robertson S, Martínez GJ, Payet CA, et al. Colchicine therapy in acute coronary syndrome patients acts on caspase-1 to suppress NLRP3 inflammasome monocyte activation. Clin Sci (Lond). 2016;130(14):1237–1246. doi:10.1042/CS2016009027129183
   PubMed Web of Science ®Google Scholar
• Nidorf SM, Eikelboom JW, Thompson PL. Targeting cholesterol crystal-induced inflammation for the secondary prevention of cardiovascular disease. J Cardiovasc Pharmacol Ther. 2014;19(1):45–52. doi:10.1177/107424841349997224038016
   PubMed Web of Science ®Google Scholar
• Verneuil L, Ze Bekolo R, Dompmartin A, Comoz F, Marcelli C, Leroy D. Efficiency of colchicine and corticosteroids in a leg ulceration with cholesterol embolism in a woman with rheumatoid arthritis. Rheumatology (Oxford). 2003;42(8):1014–1016. doi:10.1093/rheumatology/keg25212869676
   PubMed Web of Science ®Google Scholar
• Keen RR, McCarthy WJ, Shireman PK, et al. Surgical management of atheroembolization. J Vasc Surg. 1995;21(5):773.7769735
   PubMed Web of Science ®Google Scholar
• Matchett W, McFarland D, Eidt J, Moursi M. Blue toe syndrome: treatment with intra-arterial stents and review of therapies. J Vasc Interv Radiol. 2000;11:585–592. doi:10.1016/S1051-0443(07)61610-810834489
   PubMed Web of Science ®Google Scholar
• Agrawal A, Ziccardi MR, Witzke C, Palacios I, Rangaswami J. Cholesterol embolization syndrome: an under-recognized entity in cardiovascular interventions. J Interv Cardiol. 2018;31(3):407–415. doi:10.1111/joic.1248329243285
   PubMed Web of Science ®Google Scholar
• Ridker PM, Everett BM, Thuren T, et al.; CANTOS Trial Group. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119–1131.28845751
   PubMed Web of Science ®Google Scholar